-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IWhsyHxk1CJeI0Gz1ffEy/plFxzKh2+uGD9i6pGQLCZt8Nv153k//sPXKLhpwfcH 5bFkCSnQ40PizeKbOltVVQ== 0001193125-10-221161.txt : 20100930 0001193125-10-221161.hdr.sgml : 20100930 20100930165128 ACCESSION NUMBER: 0001193125-10-221161 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100930 ITEM INFORMATION: Other Events FILED AS OF DATE: 20100930 DATE AS OF CHANGE: 20100930 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Neogenix Oncology Inc CENTRAL INDEX KEY: 0001341293 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: MD FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-53963 FILM NUMBER: 101099772 BUSINESS ADDRESS: STREET 1: 445 NORTHERN BLVD STE 24 CITY: GREAT NECK STATE: NY ZIP: 11021 BUSINESS PHONE: 516-482-1200 MAIL ADDRESS: STREET 1: 445 NORTHERN BLVD STE 24 CITY: GREAT NECK STATE: NY ZIP: 11021 8-K 1 d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 30, 2010

 

 

NEOGENIX ONCOLOGY, INC.

(Exact name of Registrant as Specified in its Charter)

 

 

 

Maryland   0-53963   16-1697150

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

445 Northern Boulevard, Suite 24

Great Neck, NY

   11021

(Address of Principal Executive Offices)

   (Zip Code)

(516) 482-1200

Registrant’s telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2-(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01. Other Events.

On September 30, 2010, we closed a capital raise of $846,225 through the sale of 67,698 shares of our common stock at a price per share of $12.50 in a private placement.

 

-2-

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunder duly authorized.

 

NEOGENIX ONCOLOGY, INC.
By:  

/s/ Dr. Philip Arlen

  Dr. Philip Arlen
  Chief Executive Officer

Date: September 30, 2010

 

-3-

-----END PRIVACY-ENHANCED MESSAGE-----